These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16729724)

  • 1. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline.
    Ding C; Jones G
    Curr Opin Investig Drugs; 2006 May; 7(5):464-72. PubMed ID: 16729724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
    Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG; Fusco BE
    Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belimumab: anti-BLyS monoclonal antibody; Benlysta; BmAb; LymphoStat-B.
    Drugs R D; 2010; 10(1):55-65. PubMed ID: 20509716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
    Navarra SV; Guzmán RM; Gallacher AE; Hall S; Levy RA; Jimenez RE; Li EK; Thomas M; Kim HY; León MG; Tanasescu C; Nasonov E; Lan JL; Pineda L; Zhong ZJ; Freimuth W; Petri MA;
    Lancet; 2011 Feb; 377(9767):721-31. PubMed ID: 21296403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.
    Wiglesworth AK; Ennis KM; Kockler DR
    Ann Pharmacother; 2010 Dec; 44(12):1955-61. PubMed ID: 21081710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
    Mosak J; Furie R
    Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists.
    Stohl W
    Curr Dir Autoimmun; 2005; 8():289-304. PubMed ID: 15564726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
    Dennis GJ
    Clin Pharmacol Ther; 2012 Jan; 91(1):143-9. PubMed ID: 22130121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Belimumab--an anti-BLyS human monoclonal antibody for rheumatoid arthritis.
    Jin X; Ding C
    Expert Opin Biol Ther; 2013 Feb; 13(2):315-22. PubMed ID: 23268610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
    Espinosa G; Cervera R
    Drugs Today (Barc); 2010 Dec; 46(12):891-9. PubMed ID: 21589946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Belimumab for the management of systemic lupus erythematosus.
    Lutalo PM; D'Cruz DP
    Expert Opin Biol Ther; 2012 Jul; 12(7):957-63. PubMed ID: 22646798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
    Furie R; Stohl W; Ginzler EM; Becker M; Mishra N; Chatham W; Merrill JT; Weinstein A; McCune WJ; Zhong J; Cai W; Freimuth W;
    Arthritis Res Ther; 2008; 10(5):R109. PubMed ID: 18786258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the BLyS-APRIL signaling pathway in SLE.
    La Cava A
    Clin Immunol; 2013 Sep; 148(3):322-7. PubMed ID: 23269199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Belimumab: a guide to its use in systemic lupus erythematosus.
    Scott LJ; Burness CB; McCormack PL
    BioDrugs; 2012 Jun; 26(3):195-9. PubMed ID: 22428610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
    Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
    Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B cell targeted therapies in autoimmune diseases.
    Isenberg DA
    J Rheumatol Suppl; 2006 May; 77():24-8. PubMed ID: 16652442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?
    Runkel L; Stacey J
    Expert Opin Biol Ther; 2014 Apr; 14(4):491-501. PubMed ID: 24490627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.